Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT4706 and BAT1308 in Advanced Solid Tumors
NCT06139536Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BAT-4706 in solid tumor (5 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 21 days, Vital signs at 1 year and 5 more. Started Mar 2024; status: completed.
02
Drugs
BAT-4706
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06139536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139536.